Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04250155 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Genentech.
- Active
- Registry status
- Phase 1
- Development phase
- 195
- Enrollment target
- 20
- Study locations
NCT04250155 is a Phase 1 study of Solid Tumors that is active but no longer recruiting, run by Genentech. The registered enrollment target is 195 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04250155, a Phase 1 study of Solid Tumors, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 195 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG XmAb24306
Study Locations (20)
Other
- Instituto do Cancer do Estado de Sao Paulo - ICESP - São Paulo
- Universitair Medisch Centrum Groningen - Groningen
- Seoul National University Bundang Hospital - Seongnam-si
- Seoul National University Hospital - Seoul
- Severance Hospital Yonsei University Health System - PPDS - Seoul
- Asan Medical Center - PPDS - Seoul
Lombardy
- Fondazione IRCCS Istituto Nazionale dei Tumori - Milan
- Istituto Europeo Di Oncologia - Milan
- Istituto Clinico Humanitas - Rozzano
California
- Stanford Health Centre - Palo Alto - Palo Alto
- University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center - San Francisco
Arizona
- Honor Health Research Institute - Scottsdale
Connecticut
- Yale University - New Haven
Michigan
- City of Hope Comprehensive Cancer Center - Ann Arbor
Tennessee
- SCRI Oncology Partners - Nashville
Victoria
- Parkville Cancer Clinical Trial Unit (PCCTU) - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2020-03-09 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04250155
The ClinicalTrials.gov registry entry for NCT04250155 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (31% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04250155 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Lombardy, California.
Frequently Asked Questions
What is clinical trial NCT04250155 about?
NCT04250155 is a clinical study titled "An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors". This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
What is the current status of trial NCT04250155?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 195 participants. The study started on 2020-03-09. Estimated completion is 2026-06-15.
What conditions does trial NCT04250155 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT04250155?
The interventions under investigation include: Atezolizumab (DRUG), XmAb24306 (DRUG).
Who is sponsoring clinical trial NCT04250155?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04250155 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.